ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.

[1]  A. Sangoi,et al.  Prostate Adenocarcinomas Aberrantly Expressing p63 Are Molecularly Distinct from Usual-Type Prostatic Adenocarcinomas , 2014, Modern Pathology.

[2]  G. Kristiansen,et al.  Comparison of p40 (ΔNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? , 2013, Histopathology.

[3]  Yan Geng,et al.  p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia , 2013, Proceedings of the National Academy of Sciences.

[4]  Giuseppe Pelosi,et al.  p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma , 2012, Modern Pathology.

[5]  A. D. De Marzo,et al.  A Case of Prostatic Adenocarcinoma With Aberrant p63 Expression: Presentation With Detailed Immunohistochemical Study and FISH Analysis , 2011, International journal of surgical pathology.

[6]  R. Vessella,et al.  Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells , 2009, The Prostate.

[7]  R. Dhir.  Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases , 2009 .

[8]  J. Epstein,et al.  False Positive Labeling of Prostate Cancer With High Molecular Weight Cytokeratin: p63 a More Specific Immunomarker for Basal Cells , 2008, The American journal of surgical pathology.

[9]  J. Epstein,et al.  The Role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the Prostate , 2007, The American journal of surgical pathology.

[10]  J. Epstein,et al.  Basal Cell Carcinoma of the Prostate: A Clinicopathologic Study of 29 Cases , 2007, The American journal of surgical pathology.

[11]  Soo Yong Tan,et al.  Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. , 2007, American journal of clinical pathology.

[12]  R. Shah,et al.  Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. , 2006, American journal of clinical pathology.

[13]  J. Epstein.  Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy , 2004, Modern Pathology.

[14]  H. Geddert,et al.  The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. , 2003, Human pathology.

[15]  J. Reis-Filho,et al.  Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray , 2003, Virchows Archiv.

[16]  A. Scarpa,et al.  Constitutive expression of ΔN-p63α isoform in human thymus and thymic epithelial tumours , 2003, Virchows Archiv.

[17]  M. Rubin,et al.  Basal Cell Cocktail (34&bgr;E12 + p63) Improves the Detection of Prostate Basal Cells , 2003, The American journal of surgical pathology.

[18]  A. Scarpa,et al.  Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. , 2003, Virchows Archiv : an international journal of pathology.

[19]  M. Loda,et al.  Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells , 2002, Modern Pathology.

[20]  R. Shah,et al.  Comparison of the Basal Cell-Specific Markers, 34&bgr;E12 and p63, in the Diagnosis of Prostate Cancer , 2002, The American journal of surgical pathology.

[21]  W. Gage,et al.  p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. , 2001, Urology.

[22]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[23]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.